September 28, 2020

Significant biosimilar activities this week include:

  • 21 Sep 20, EU: Alexion announced it has received a positive opinion from the EU's CHMP for a new 100mg/mL formulation of Ultomiris® (ravulizumab).  The new formulation requires an infusion time of 0.4 hours to 1.3...

Significant biosimilar activities this week include:

  • June 08: the Centre for Biosimilars reported that the WHO certified Celltrion's Truxima® (rituximab) in its prequalification program. This program assesses clinical and other data related to biosimilars, and aims...

Significant biosimilar activities this week include:

  • May 29: in a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to m...

29 May 2020 | US | Alexion, Amgen | In a filing to the Securities and Exchange Commission, Alexion announces it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 Ma...

Please reload

Biosimilars bulletin 

October 4, 2020

Please reload

Search by tags